Chapalain J C, Guibourdenche M, Perrier-Gros-Claude J D, Bartoli M, Riou J Y
Laboratoire de Biologie Médicale, Hôpital d'Instruction des Armées Desgenettes, Lyon, France.
Pathol Biol (Paris). 1992 Mar;40(3):230-3.
Since February 5th 1990, the prevention of secondary cases of cerebrospinal meningitis (CSM) in France has been obtained by the use of rifampin. Following the detection of a case of N. meningitidis of antigenic formula B:NT:P1.15,16 in a military population, 89 contacts subjects received 600 mg rifampin twice a day during 2 days. Meningococcal carriage rate was investigated by nasopharyngeal swab sampling of the 89 subjects and 62 non-contact controls from the same community. Twenty-three days after the initial case of meningitis, carriage rate was 5.6% for treated subjects and 37.1 for controls. Sero-grouping, serotyping and subtyping failed to detect the initial virulent strain; it demonstrated the heterogeneity of circulating strains. Since rifampin-resistant mutants may occur, two strains in the treated group, it is essential that chemoprophylaxis in a community be limited strictly to the contact subjects.
自1990年2月5日起，法国通过使用利福平来预防脑脊髓膜炎（CSM）的二代病例。在某军事人群中检测到1例抗原型为B:NT:P1.15,16的脑膜炎奈瑟菌病例后，89名接触者在2天内每天两次接受600毫克利福平治疗。通过对这89名受试者以及来自同一社区的62名非接触对照者进行鼻咽拭子采样，调查脑膜炎球菌携带率。在首例脑膜炎病例出现23天后，接受治疗的受试者携带率为5.6%，而对照者为37.1%。血清群分型、血清型分型和亚型分型均未能检测到最初的致病菌株；这表明了流行菌株的异质性。由于治疗组可能出现利福平耐药突变株，因此社区中的化学预防必须严格限于接触者。
